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Abstract
Background: Rhabdomyosarcoma (RMS) is a malignant soft tissue sarcoma of childhood including
two major histological subtypes, alveolar (ARMS) and embryonal (ERMS) RMS. Like other human
malignancies RMS possesses high metastatic potential, more pronounced in ARMS than in ERMS.
This feature is influenced by several biological molecules, including soluble factors secreted by
tumor cells, such as heparanase (HPSE). HPSE is an endo-β-D-glucuronidase that cleaves heparan
sulphate proteoglycans.
Methods: We determined HPSE expression by Western blot analysis in ARMS and ERMS cells
lines and activity in supernatants by an ELISA assay. Stable HPSE silencing has been performed by
shRNA technique in RH30 and RD cell lines and their invasiveness has been evaluated by Matrigel-
invasion assay. HPSE activity and mRNA expression have also been quantified in plasma and biopsies
from RMS patients.
Results: HPSE expression and activity have been detected in all RMS cell lines. Stable HPSE
silencing by shRNA technique determined a significant knockdown of gene expression equal to 76%
and 58% in RH30 and RD cell lines respectively and induced a less invasive behaviour compared to
untreated cells. Finally, we observed that HPSE mRNA expression in biopsies was higher than in
foetal skeletal muscle and that plasma from RMS patients displayed significantly more elevated HPSE
levels than healthy subjects with a trend to higher levels in ARMS.
Conclusion: In conclusion, our data demonstrate for the first time HPSE expression and activity
in RMS and highlight its involvement in tumor cell invasion as revealed by shRNA silencing.
Moreover, HPSE expression in RMS patients is significantly higher with respect to healthy subjects.
Further studies are warranted to assess possible relationships between HPSE and clinical behaviour
in RMS.
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Background
Rhabdomyosarcoma (RMS) is the most common soft-tis-
sue cancer occurring in childhood. It originates from
primitive mesenchymal cells committed to myogenic dif-
ferentiation. RMS belongs to the broader category of small
blue round cell tumors of childhood and histologically
resembles normal foetal skeletal muscle [1]. It can be clas-
sified into two main histological subtypes with distinct
appearances and clinical behaviours. The rarer alveolar
type (ARMS) arises mainly in the extremities and trunk. It
is also associated with worse prognosis and higher disease
stage at diagnosis. The unfavourable prognosis is related
to the propensity for early and wide dissemination, often
involving the lungs, bone marrow and bones and poor
response to chemotherapy. In contrast, the embryonal
rhabdomyosarcoma (ERMS) usually affects younger chil-
dren, at more favourable sites, and shows a less aggressive
clinical behaviour than ARMS [2,3].
The frequent tumor dissemination and metastasis charac-
teristics of ARMS, less common in ERMS, suggest a differ-
ent expression of molecules involved in these events
between the two subtypes. An important process in host
tissue invasion is the extracellular matrix (ECM) degrada-
tion due to secreted and cell surface bound protease and
glycosidase activities. These ECM-remodelling enzymes
affect and modify cell and tissue functions [4]. The ECM
is composed of a complex network of macromolecules
which fills the extracellular space in tissues and provides
an essential physical barrier among cells, as well as a
molecular scaffold for cell growth, migration, differentia-
tion and survival. It also undergoes continuous remodel-
ling during development and in a variety of pathological
conditions such as cancer. While intensive research
focused on enzymes capable of degrading protein compo-
nents in the ECM has been established [5,6], presently
attention is directed towards enzymes (e.g., heparanase)
cleaving glycosaminoglycan side chains. The heparan sul-
phate proteoglycans (HSPGs), the main polysaccharide
component of the ECM, are ubiquitous macromolecules
associated with the cell surface and the ECM of a wide
range of cells in vertebrate and invertebrate tissues.
Heparan sulphate (HS) plays a key role in the self-assem-
bly and integrity of the ECM. In fact, HS chains can bind
large number of proteins and several bioactive molecules
like growth factors, chemokines, cytokines and enzymes
to the cell surface and ECM, thereby regulating their avail-
ability and function in the control of some physiological
processes, such as cell-cell and cell-ECM interactions [7].
Malignant tumor growth, neo-vascularization and metas-
tasis represent pathological invasive phenomena that
involve the enzymatic degradation of the ECM. Hepara-
nase (HPSE) is an endo-β-D-glucuronidase that cleaves
HS side chains of HSPGs. Heparanase cleavage of HS in
the ECM, particularly in epithelial and sub-endothelial
basement membranes, is a critical step in cancer develop-
ment and progression in correlation with metastatic
potential, tumor vascularity and reduced survival of can-
cer patients [8]. Its activity is regulated by gene expression
and pro-enzyme activation. In fact heparanase is synthe-
sized as a 65 kDa inactive precursor whose activation
involves proteolytic cleavage, resulting in 8 and 50 kDa
protein subunits that heterodimerize to form the active
enzyme. Remarkably, the active form of heparanase is
secreted in the extracellular environment [9,10]. Recent
studies have shown that this enzyme is upregulated in an
increasing number of primary human tumors providing a
strong clinical support for its pro-metastatic and pro-ang-
iogenic features [11,12], thus making it a promising target
for the development of anti-cancer treatments [13,14].
In contrast to frequent cancers occurring in adults, little
information is available on RMS with regard to molecules
involved in tumor invasion. We analyzed HPSE expres-
sion and activity in ARMS and ERMS cell lines and inves-
tigated the relationships of the different metastatic
phenotype of ARMS and ERMS with expression and activ-
ity of heparanase.
Methods
Cell cultures
Human alveolar rhabdomyosarcoma (ARMS) cell lines
RH30, RH4, RH18, RH28 and human embryonal rhab-
domyosarcoma (ERMS) cell lines RD, SMS-CTR, RH36,
CCA were grown in RPMI (EuroClone, Pavia, Italy) sup-
plemented with 10% foetal bovine serum (Biochrom AG,
Berlin, Germany), 2 mM L-glutamine, penicillin (100 U/
ml) and streptomycin (100 μg/ml). All cell lines were
maintained at 37°C in a 5% CO2 water-saturated atmos-
phere.
Plasma and tumor RNA collection from RMS patients
A total of 3 ml of peripheral blood was obtained at the
time of diagnosis in sodium citrate [15]. All plasma sam-
ples were aliquoted, frozen at -80°C until analysis and
thawed once.
The plasma study cohort consisted of 15 paediatric
patients (5 with ARMS, 10 with ERMS) and 10 healthy
subjects as control. In 12 out of 15 RMS cases (3 ARMS, 9
ERMS), tumor tissue was available for RNA purification.
For RMS patients, the mean age was 6.3 years (range 1 –
15 yrs) with 8 girls and 7 boys at the time of diagnosis
while, for healthy subjects, the mean age was 8.9 years
(range 2 – 13 yrs) with 3 girls and 7 boys. Informed paren-
tal consent was obtained in each case.
RNA extraction and cDNA synthesis
Total RNA was extracted from cell monolayers using the
"GenElute Mammalian Total RNA Miniprep" Kit (Sigma-BMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
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Aldrich, Milan, Italy) including DNase treatment
(DNASE70, Sigma), according to manufacturer's instruc-
tions.
Tumor RNA was isolated by using RNA-zol (Tel-Test,
Friendswood, USA) following the manufacturer's instruc-
tions.
Yield and purity were checked by Nanodrop (EuroClone).
1 μg of total RNA from each sample was reverse tran-
scribed into cDNA using 500 ng random primers and 200
U SuperScript II Reverse Transcriptase (Invitrogen, Milan,
Italy).
Cloning of HPSE and GAPDH to obtain an internal 
standard
Total RNA from RH30 cells was reverse transcribed and
subsequently subjected to PCR amplification by using
HPSE and GAPDH specific primers (Table 1). The PCR
products (136 bp for HPSE and 112 bp for GAPDH) were
electrophoresed on a 2% agarose gel in 1× TAE buffer [50
mM Tris-HCl (pH 8.0), 20 mM sodium acetate, 2 mM
Na2EDTA] and visualized by ethidium bromide staining.
After isolation they were purified with the "QIAquickTM
Gel Extraction" Kit (Qiagen, Milan, Italy) and subse-
quently cloned directly into pCR®II-TOPO® Vector (TOPO
TA Cloning®  system, Invitrogen). They were then
sequenced on both strands using Big Dye terminator v3.1
protocol on ABI PRISM 310 Genetic Analyzer (Applied
Biosystems, Milan, Italy).
Quantitative Real-time PCR
We performed a quantitative Real-time PCR assay based
on the use of SYBR Green I (Applied Biosystems) as fluo-
rescent intercalation dye into double-stranded DNA dur-
ing the amplification cycles. The assays were performed in
96 multi-well PCR plates covered with optical tapes in the
Applied Biosystems 7500 Real-time PCR System in a final
volume of 25 μl, containing 10 ng of cDNA, 12.5 μl of
Power Master Mix 2X (Applied Biosystems), 5 μmoles of
either  HPSE, Matrix Metalloproteinases (MMPs) or
GAPDH forward and reverse primers, and water. The spe-
cific primer sequences are listed in Table 1.
The reaction was subjected to denaturation at 95°C for 10
minutes followed by 40 cycles of denaturation at 95°C for
30 seconds, annealing and elongation at 60°C for 1
minute.HPSE mRNA expression levels were evaluated by
an absolute quantitative Real-time PCR in RMS cell lines
and biopsies from RMS patients. Plasmids containing
HPSE and GAPDH fragments were used as templates to
obtain the standard curves. The relative HPSE  mRNA
expression levels were described as HPSE copy number/
GAPDH copy number ratios. After the amplification, the
software directly defined the standard curve of the experi-
ment based on the Ct for each gene in analysis. In this
way, a linear regression line was plotted and the resulting
equation was used to calculate the copy number for the
unknown samples [16].MMPs  mRNA expression levels
were evaluated by a relative quantitative Real-time PCR in
RMS cell lines and normalized to GAPDH. The compara-
tive Ct method (ΔΔCt) was used to quantify MMPs gene
expression and the relative quantification (RQ) was calcu-
lated as 2-ΔΔCt. MMP2 expression level in RH30 wild type
cell line was regarded as 100% and MMP2, MMP9 and
MMP14 levels in the other samples were calculated rela-
tive to this value.
Western blot
Sub-confluent cells were washed with PBS, lysed and
scraped in lysis buffer [50 mM Tris-HCl (pH 5.0), 150 mM
NaCl, 0.01% Triton X-100] with Protease Inhibitor Cock-
tail "Complete" (Roche, Milan, Italy). Cellular lysates
were sonicated, centrifuged at 4°C for 30 minutes at
15,000 × g and finally quantified using Bio-Rad Protein
Assay (Bio-Rad, Milan, Italy). Total proteins (50 μg) and
platelet extract (5 μg) used as positive control were treated
in reducing sample buffer [2% SDS, 80 mM Tris-HCl (pH
6.8), 10% glycerol, 0.005% bromophenol blue, 10% β-
mercaptoethanol] and boiled for 10 minutes. Subse-
quently the samples were resolved in 9% SDS-PAGE and
electro-transferred for 2.5 hours at 4°C to nitrocellulose
membranes. Membranes were exposed to primary poly-
clonal antibody (sc-25825, Santa Cruz Biotechnolgy,
Santa Cruz, CA). After three washes in TBST [20 mM Tris-
HCl (pH 7.4), 150 mM NaCl, 0.05% Tween-20], the
membranes were incubated with a secondary peroxidase-
conjugated antibody (sc-2004, Santa Cruz Biotechnol-
ogy). The signal was detected by "SuperSignals West Pico
Chemiluminescent" substrate solution (Pierce, Rockford,
IL), according to the manufacturer's instructions.
HPSE ELISA
The quantitative detection of HPSE in RMS cell culture
supernatants was performed with "Heparanase assay" Kit
Table 1: primers sequences
Gene Sequences 5'→ 3'
HPSE d – ATTTGAATGGACGGACTGC
r – GTTTCTCCTAACCAGACCTTC
MMP2 d – GCGGCGGTCACAGCTACTT
r – CACGCTCTTCAGACTTTGGTTCT
MMP9 d – CCTGGAGACCTGAGAACCAATC
r – CCACCCGAGTGTAACCATAGC
MMP14 d – TGCCATGCAGAAGTTTTACGG
r – TCCTTCGAACATTGGCCTTG
GAPDH d – ACACCCACTCCTCCACCTTT
r – TCCACCACCCTGTTGCTGTABMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
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from AMS Biotechnology (Milton Abingdon, Oxon, UK)
according to the manufacturer's instructions. Briefly, the
ELISA plate was rehydratated by adding 100 μl of PBS and
incubated at room temperature for 30 minutes. After
removing PBS, 50 μl of the reaction buffer and 50 μl of
samples were added in each well. 50 μl of reaction buffer
and 50 μl of platelet protein extract diluted 1:100 in 1×
Heparanase buffer were used as negative and positive con-
trols respectively. The samples were serum-free condi-
tioned media obtained from the different cell lines. The
micro-well plate was then incubated 1 hour at 37°C and
then each well was washed four times with PBT [PBS +
0.1% v/v Tween-20] and subsequently twice with PBS. To
each well was added100 μl of the supplied Strep-HRP
complex and incubated 1 hour at room temperature on a
plate shaker. The micro-well plate was washed five times
with PBS and subsequently 100 μl of peroxidase substrate
were added at room temperature. The plate was gently
shaken and the absorbance determined at 450 nm in an
ELISA plate reader. Activity of each sample was calculated
as described by the manufacturer and represented as ng of
HS removed per minute.
Transfection of HPSE shRNA plasmid into RH30 and RD 
cell lines
To obtain stably HPSE silenced cell lines, we used four dif-
ferent shRNAs targeting human heparanase
(NM_006665). The sequence of the 29 mer shRNAs are
listed in Table 2.
The HPSE gene-specific shRNA expression cassettes as well
as the negative control shRNA pRS plasmid (TR20003)
and the negative control shRNA pRS non-effective GFP
plasmid (TR30003), were purchased from OriGene
(Rockville, MD, USA). Transcribed shRNAs were reconsti-
tuted with 50 μl of RNase-Free water (Gibco, Invitrogen)
to prepare a 100 ng/μl stock solution. RH30 and RD cell
lines were seeded in 6-well plates at a density of 2.0 × 105
and 1.5 × 105 cells per well respectively. After 24 hours,
cells at 70 – 80% confluence were transfected with 2 μg of
each shRNA plasmid in serum-free medium using Tran-
sIT-LT1 transfection reagent (Mirus, Madison, WI) accord-
ing to the manufacture's instruction. Control cells were
treated with the same amount of TransIT-LT1 transfection
reagent (Mock). 48 hours after transfection, RH30 and RD
cells were placed for some weeks under selection with 0.5
and 1.0 μg/ml of puromycin (Sigma) respectively. From
RH30 and RD cell lines, three different stable clones were
selected for subsequent analysis.
Proliferation assay
The proliferation of RH30 and RD cell lines was evaluated
by MTT assay. For both cell lines, wild type and silenced
cells were tested as well as the relative negative controls.
Cells in mid-log phase were seeded in 96-well culture
plate and cultured for 24, 48 and 72 hours in their
medium. Subsequently 10 μl of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5
mg/ml in phosphate-buffered saline) was added to each
well, cells were incubated for 4 h at 37°C and the precip-
itates were dissolved in 150 μl of dimethyl sulfoxide. The
number of proliferating cells was evaluated by measuring
optical density at 540 nm on a microtiter plate reader.
Invasion assay
The invasive behaviour of ARMS RH30 and ERMS RD cell
lines was assessed by using the Boyden-chamber assay
according to the method of Albini et al. [17], with slight
modifications. For both cell lines, wild type and silenced
cells were tested as well as the relative negative controls.
The filters used in the assay were "Isopore Membrane Fil-
ters" (Millipore, Milan, Italy) with pore size of 8.0 μm. Fil-
ters were coated with 50 μl of Matrigel solution (BD
Biosciences, Milan, Italy), an artificial basement mem-
brane that contains abundant HSPGs, previously pre-
pared at a concentration of 0.225 μg/μl. Tumor cells (2.0
× 105 cells/ml) resuspended in 800 μl serum-free medium
were layered on top of the polymerized gel in the upper
compartment of the chamber while, in the lower compart-
ment, conditioned serum-free medium from NIH3T3 cell
line was used as chemo-attractant. After 5-hour incuba-
tion at 37°C, Matrigel was removed, the filters were
washed in water, fixed in 100% ethanol for 5 minutes and
stained with 1% toluidine blue/1% sodium tetraborate
for 2 minutes. After staining, the filters were let to dry and
photographed using Canon PowerShot G6 camera.
Images were analyzed by ImageJ software http://
rsb.info.nih.gov/ij/.
HPSE plasma assay
HPSE plasma activity was quantified according to the
method of Xu et al. [18]. This assay is based on the ability
of HPSE to degrade heparan-sulphate proteoglycans
present in the Matrigel. 25 μl of Matrigel was dissolved in
ice-cold PBS at a concentration of 200 μg/ml and used to
coat ELISA plates and left to dry at room temperature for
1.5 hour. Samples were diluted at 1:4 in HPSE buffer [0.1
M Sodium Acetate (pH 5.0), 0.1 mg/ml BSA, 0.01% Triton
X-100, Protease Inhibitor Cocktail]. The plates were
washed once with PBT [PBS + 0.05% v/v Tween-20] and
then samples were added and incubated overnight at
Table 2: shRNA 29 mer sequences
shRNA Sequences
pHPSE-1 TTATGTGGCTGGATAAATTGGGCCTGTCA
pHPSE-2 GTTCAAGAACAGCACCTACTCAAGAAGCT
pHPSE-3 GTGGTGATGAGGCAAGTATTCTTTGGAGC
pHPSE-4 TCGTTCCTGTCCGTCACCATTGACGCCAABMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
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37°C. The wells were washed with PBT and blocked with
the appropriate buffer [PBT, 0.5% BSA, 1 mM EDTA] at
room temperature for 2 hours. After PBT washing, pri-
mary monoclonal antibody anti-HS (clone HepSS-1, Seik-
agaku, Tokyo, Japan) diluted 1:500 was added and
incubated in blocking buffer at room temperature for 1
hour. After PBT washing, goat anti-mouse IgM-HRP sec-
ondary antibody (sc-2973, Santa Cruz Biotechnology)
diluted 1:1000 was added and incubated at room temper-
ature for 1 hour. Then 50 μl of the ABTS [2,2-azino-bis-(3-
ethylbenzthiazoline-6-sulphonic acid), Sigma] was added
to each well. Finally, the reaction was blocked with 50 μl
per well of 1% SDS and the OD405 absorbance was read
in an ELISA plate reader.
HPSE activity in each plasma sample was calculated as the
difference between the OD405 value with or without
heparin (Sigma) at the final concentration of 50 μg/ml.
This inhibitor was used to ensure the detection of the spe-
cific HPSE activity in plasma samples.
Statistical analysis
Differences in HPSE plasma levels and HPSE expression
between RMS patients and controls were evaluated using
the Mann-Whitney test with Bonferroni's Multiple Com-
parison correction. Differences between wild type and
HPSE silenced cells were compared using the Students' t-
test. A p value ≤ 0.05 was considered as the level of signif-
icance for all tests.
Results
HPSE expression in RMS cell lines
In order to define whether heparanase was expressed in
the two major RMS histotypes and whether gene expres-
sion correlated with their different metastatic potential,
HPSE expression was evaluated in ARMS and ERMS cell
lines. Results from absolute quantitative Real-time PCR
assay revealed a similar mRNA expression among all cell
lines analyzed (data not shown). Subsequently, we per-
formed Western blot analysis to detect HPSE protein in
total cell lysates of the same cell lines. Primary polyclonal
HPSE antibody was able to recognize both the active (50
kDa) and inactive (65 kDa) isoforms of the enzyme. As
shown in Figure 1, both HPSE isoforms were detected in
all cell lines under investigation. In particular, ARMS cell
lines displayed two different patterns: RH30 and RH4 cell
lines were characterized by high levels of the active iso-
form and low levels of the inactive one, whereas RH18
and RH28 showed a low expression of the active enzyme.
Similarly, all ERMS cell lines displayed low levels of active
HPSE isoform.
HPSE activity in RMS cell lines
HPSE activity in serum-free conditioned media of RMS
cell lines was quantified by ELISA assay. The enzymatic
activity was expressed as nanograms of HS removed per
minute. A marked HPSE activity level could be observed
in RH30, RH18 and RH28 as well as in RD and SMS-CTR
cells. These cell lines showed enzymatic activity compara-
ble to that of platelets, used as a positive control. Differ-
ently, RH4, RH36 and CCA cells displayed a lower
enzymatic activity (Figure 2).
Stable HPSE silencing of RH30 and RD cell lines and 
invasion assay
To further investigate the role of HPSE expression in RMS,
we downregulated HPSE in RH30 and RD cell lines. In
particular, from each 29 mer-shRNA targeting HPSE and
the relative negative controls, we obtained three clones
under puromycin selection. We evaluated HPSE mRNA
expression in all clones by Real-time PCR analysis (data
not shown) and we chose the pHPSE-3 sequence that
showed the best silencing rate in both cell lines. In this
way we obtained a significant knockdown of gene expres-
Heparanase expression in rhabdomyosarcoma cell lines Figure 1
Heparanase expression in rhabdomyosarcoma cell 
lines. Western blot analysis was performed to detect HPSE 
in total cell lysates. Platelet extract and GAPDH were 
included as positive and loading controls respectively. One of 
three independent experiments is reported.
Heparanase activity in serum-free conditioned media of rhab- domyosarcoma cell lines Figure 2
Heparanase activity in serum-free conditioned media 
of rhabdomyosarcoma cell lines. The enzymatic activity 
is expressed as nanograms of heparan sulphate (HS) removed 
per minute. The results represent the mean ± standard devi-
ation of three independent experiments performed in dupli-
cate. Platelet extract was used as positive control (PC, white 
bar); ARMS (black bars); ERMS (grey bars).BMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
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sion equal to 76% and 58% for RH30 and RD, respec-
tively (P < 0.05) (Figure 3A). A clear reduction in HPSE
protein expression was observed in total cell lysate (Figure
3B). As regards with HPSE activity in serum-free condi-
tioned media from untreated and silenced RH30 and RD
cells, we detected a remarkable reduction equal to 70%
and 87%, respectively (P < 0.05) (Figure 3C). HPSE
expression was comparable in wild type cell lines and in
negative control clones (data not shown).
MTT assay did not reveal any differences in cell prolifera-
tion between wild type and silenced cells (data not
shown).
Since the ability of malignant cells to invade Matrigel-
coated filters represents a measure of their invasiveness,
an invasion assay was carried out. We compared RH30
and RD wild type cells with the corresponding silenced
cells. As shown in Figure 4, RH30 wild type cells were
more invasive than RD wild type cells. As to the role of
HPSE in the invasiveness, silenced RH30 and RD cells
showed an invasive capacity reduced by 67% and 91% (P
< 0.05) of controls, respectively.
MMPs expression in RH30 and RD cell lines after stable 
HPSE silencing
In order to define whether MMPs expression changes after
HPSE silencing, we evaluated MMP2, MMP9 and MMP14
expression in RH30 and RD wild type cells and in the cor-
responding silenced cells by a relative quantitative Real-
time PCR.
As shown in Figure 5, RH30 silenced cells displayed a not
significant faint decrease of all MMPs expression levels
with respect to control, whereas in RD wild type and
silenced cells MMPs level remained substantially equal.
On the whole MMP2 and MMP14 expression was higher
in the alveolar RH30 cells respect to the embryonal RD.
HPSE expression and activity in RMS patients
HPSE expression was evaluated in 12 RMS biopsies by an
absolute quantitative Real-time PCR, using normal foetal
skeletal muscle cDNA as control.
HPSE mRNA expression was significantly higher in biop-
sies of RMS patients compared to foetal skeletal muscle (P
< 0.05) (Figure 6A).
HPSE activity in plasma samples collected at diagnosis
from 15 RMS patients and from 10 healthy subjects was
determined by an ELISA method. As shown in Figure 6B,
we demonstrated that HPSE activity was significantly
higher in plasma of RMS patients compared to healthy
controls (P = 0.001). In addition, the five plasma samples
Stable heparanase silencing of RH30 and RD cell lines with  shRNA Figure 3
Stable heparanase silencing of RH30 and RD cell lines 
with shRNA. (A) HPSE mRNA expression levels in control 
(black bars) and silenced (hatched bars) RH30 and RD cell 
lines were determined by Real-time PCR. The results were 
normalized using GAPDH as internal control and represent 
the mean ± standard deviation of three samples performed in 
duplicate. (B) Western blot analysis was performed to dem-
onstrate HPSE silencing between control and silenced RH30 
and RD cell lines. GAPDH was included as loading control. 
(C) Heparanase activity in serum-free conditioned media 
obtained from control (black bars) and silenced (hatched 
bars) RH30 and RD cell lines. The enzymatic activity is 
expressed as nanograms of heparan sulphate (HS) removed 
per minute. The results represent the mean ± standard devi-
ation of three independent experiments performed in dupli-
cate. Platelet extract was used as positive control (PC, white 
bar). An asterisk (*) indicates a significant difference from 
control (P < 0.05).BMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
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obtained from ARMS patients showed higher activity lev-
els of HPSE than ERMS, although the difference did not
reach statistical significance (data not shown).
Discussion
RMS is classified into two major histological groups: alve-
olar and embryonal. The rarer ARMS is more aggressive
and associated with a significantly worse outcome than
ERMS [3]. The more frequent tumor dissemination and
metastatic characteristic of ARMS, compared to ERMS,
suggest that different enzymatic activities may be involved
in host tissue invasion [19]. Whereas upregulation of
heparanase is well documented in an increasing number
of human solid tumors showing a correlation with their
invasive potential [20], its role has not been elucidated in
RMS thus far.
Therefore, in the present study, we investigated HPSE
expression and activity in RMS cell lines in order to estab-
lish whether any correlation between HPSE levels and his-
totype exists.
HPSE protein may be present both in the active/inactive
form. Only the active one (50 kDa) is responsible for HS
degradation in the ECM [21]. Since HPSE mRNA expres-
sion results similar in all RMS cell lines analyzed, we per-
formed a Western blot analysis to discriminate between
the two isoforms.
All RMS cell lines showed the expression of HPSE protein.
All ERMS cell lines along with RH18 and RH28 showed a
similar and moderate expression of active HPSE isoforms
and high levels of inactive HPSE isoforms. On the other
hand, RH30 and RH4 cell lines were characterized by high
levels of active HPSE and moderate expression of the inac-
In vitro invasion assay Figure 4
In vitro invasion assay. Invasiveness of RH30 and RD wt 
(wild type) cells together with RH30 and RD shRNA 
(silenced) cells was measured using a modified Boyden cham-
ber assay in the presence of NIH/3T3 cell conditioned 
medium as chemo-attractant. (A) One of three independent 
experiments is reported (magnification 400×). (B) The 
results represent the mean ± standard deviation of quintupli-
cate samples from three independent experiments. A.U., 
arbitrary unit. Control corresponds to wild type cells (black 
bars); shRNA corresponds to HPSE silenced cells (hatched 
bars). An asterisk (*) indicates a significant difference from 
control (P < 0.05).
Matrix Metalloproteinases expression in RH30 and RD cell  lines Figure 5
Matrix Metalloproteinases expression in RH30 and 
RD cell lines. MMPs mRNA expression levels in control 
(black and gray bars) and silenced (hatched bars) RH30 and 
RD cell lines were determined by Real-time PCR. The results 
were normalized using GAPDH as internal control. The 
expression level determined for MMP2 in RH30 wild type 
cells is regarded as 100% and MMPs expression in the other 
cell lines are presented as percentage relative to it. The 
results represent the mean ± standard deviation of two inde-
pendent experiments performed in triplicate.BMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
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tive one. It was interesting that the total amount of HPSE
protein, the active plus the inactive isoforms, was compa-
rable in all RMS cell lines.
Furthermore, we evaluated HPSE activity by an ELISA
assay on serum-free conditioned media from RMS cell
lines. This assay confirmed a heterogeneous HPSE activity
among RMS cell lines without a clear-cut difference
between ARMS and ERMS cell lines.
The difference between active and inactive heparanase iso-
forms in RMS cell lines lysates and the discrepancy
between the cytoplasmic amount of the enzyme and its
activity in conditioned media could be explained in light
of HPSE complex protein activation and secretion. In fact,
heparanase is synthesized as a 65 kDa inactive precursor,
shuttled to the Golgi apparatus and then secreted via ves-
icles. Once secreted, heparanase interacts with HSPGs
forming a complex which is endocytosed. Conversion of
endosome in lysosome results in HPSE cleavage, yielding
8 and 50 kDa protein subunit that heteodimerize to form
the active enzyme [22,23]. Moreover, heparanase active
heterodimer can get secreted in response to local or sys-
temic cues [12].
In order to determine the HPSE role in the ECM degrada-
tion associated with the different invasive potential in
alveolar and embryonal histotypes, we stably silenced one
cell line from each histotype by shRNA technique. Based
on the ELISA assay results, we selected ARMS RH30 and
ERMS RD cell lines characterized by the highest HPSE
activity in the conditioned media. After puromycin selec-
tion, clones appearing to be silenced more than 50% were
chosen from both cell lines. Using a Matrigel-invasion
assay, we demonstrated that HPSE silencing significantly
reduced the invasive potential of RH30 and RD cell lines
compared with the untreated cells. Although previous
experiments demonstrated a relevant role of other ECM
degrading enzymes [19], HPSE silencing emphasizes the
importance of this enzyme both in alveolar and embryo-
nal RMS invasiveness. Because Zcharia E. et al. have
recently demonstrated in a knock-out mouse model that
absence of HPSE  expression was associated with an
increased expression of MMPs [24], we determined the
effects of HPSE silencing in RH30 and RD cell lines by
analyzing the expression of MMP2, MMP9 and MMP14.
In our cellular model we did not observe the same phe-
nomenon since HPSE silencing did not result in signifi-
cant differences of MMPs expression in silenced vs. wild
type cells. In addition, after HPSE silencing, no change in
cell proliferation was observed by MTT analysis.
It has recently been observed that elevated HPSE levels in
patients' blood correlates with a poor prognosis [25]. For
Heparanase expression and activity in rhabdomyosarcoma patients Figure 6
Heparanase expression and activity in rhabdomyosarcoma patients. (A) HPSE mRNA expression levels in foetal 
skeletal muscle (white bar) and RMS patients (black bar) were determined by Real-time PCR. The results were normalized 
using GAPDH as internal control and represent the mean ± standard deviation of two independent experiments performed in 
triplicate. (B) HPSE activity in each plasma sample was calculated as difference between the O.D. 405 value with or without 
heparin at the final concentration of 50 μg/ml. An asterisk (*) indicates a significant difference between RMS patients and con-
trols (P < 0.05).BMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
Page 9 of 10
(page number not for citation purposes)
this reason we analyzed by an ELISA assay HPSE activity
in plasma samples from RMS patients and healthy sub-
jects. RMS patients showed a statistically significant
higher heparanase activity with respect to healthy individ-
uals. Coherently, a significantly higher expression of
HPSE  transcripts was assessed in biopsies from RMS
patients compared to foetal skeletal muscle tissue used as
normal counterpart of the tumor.
Although high HPSE plasma levels have been previously
reported in other paediatric malignancies [15], this is the
first demonstration of a significantly high HPSE expres-
sion in RMS patients. Additionally, although it should be
interpreted with caution due to the limited number of
patients, there is some suggestion of higher HPSE plasma
levels in ARMS compared with ERMS patients. Further
clinical and histo-pathological analyses on larger cohorts
of RMS patients are necessary to establish whether HPSE
may be considered as a novel marker able to distinguish
the more aggressive ARMS from ERMS. Since a single func-
tional heparanase has been identified so far [26], the rele-
vant effect of the specific gene knockdown described here
should encourage the development of novel heparanase-
targeting therapeutic approaches aimed at inhibiting RMS
invasive potential.
Conclusion
In conclusion, we detected for the first time HPSE expres-
sion and activity in RMS and showed its implication in
tumor cell invasiveness in vitro. We also demonstrated a
significantly high HPSE expression in RMS patients with a
trend to higher levels in ARMS.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
VM carried out immuno-blotting analysis, ELISA assays
and HPSE silencing of RMS cell lines; CM and ET carried
out qRT-PCR, cell transfections and invasion-assay. AR
evaluated the clinical aspects and together with AZ col-
lected plasma and mRNA samples of RMS patients. MO
supervised experimental work and wrote the manuscript
with the contribution of all co-authors. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by the Ministero dell'Università e della Ricerca 
(MIUR) (Cofin 2006). Further support was obtained from former 60% con-
tribution (Padova University grant), from Associazione Italiana per la 
Ricerca sul Cancro (AIRC) and from Fondazione Città della Speranza. The 
authors wish to thank Dr. Chiara Romualdi and Dr. Gloria Tridello for sta-
tistical analysis.
References
1. Merlino G, Helman LJ: Rhabdomyosarcoma – working out the
pathways.  Oncogene 1999, 18(38):5340-5348.
2. Breitfeld PP, Meyer WH: Rhabdomyosarcoma: new windows of
opportunity.  Oncologist 2005, 10(7):518-527.
3. Wijnaendts LC, Linden JC van der, van Unnik AJ, Delemarre JF, Voute
PA, Meijer CJ: Histopathological classification of childhood
rhabdomyosarcomas: relationship with clinical parameters
and prognosis.  Hum Pathol 1994, 25(9):900-907.
4. Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and
metastasis: changing views.  J Pathol 2008, 214(3):283-293.
5. Liotta LA, Kohn EC: The microenvironment of the tumour-
host interface.  Nature 2001, 411(6835):375-379.
6. Stetler-Stevenson WG, Yu AE: Proteases in invasion: matrix
metalloproteinases.  Semin Cancer Biol 2001, 11(2):143-152.
7. Yung S, Chan TM: Glycosaminoglycans and proteoglycans:
overlooked entities?  Perit Dial Int 2007, 27(Suppl 2):S104-9.
8. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A: Enzy-
matic remodeling of heparan sulfate proteoglycans within
the tumor microenvironment: growth regulation and the
prospect of new cancer therapies.  J Cell Biochem 2005,
96(5):897-905.
9. Parish CR, Freeman C, Hulett MD: Heparanase: a key enzyme
involved in cell invasion.  Biochim Biophys Acta 2001,
1471(3):M99-108.
10. Vlodavsky I, Goldshmidt O, Zcharia E, Metzger S, Chajek-Shaul T,
Atzmon R, Guatta-Rangini Z, Friedmann Y: Molecular properties
and involvement of heparanase in cancer progression and
normal development.  Biochimie 2001, 83(8):831-839.
11. Vlodavsky I, Ilan N, Naggi A, Casu B: Heparanase: structure, bio-
logical functions, and inhibition by heparin-derived mimetics
of heparan sulfate.  Curr Pharm Des 2007, 13(20):2057-2073.
12. Ilan N, Elkin M, Vlodavsky I: Regulation, function and clinical sig-
nificance of heparanase in cancer metastasis and angiogen-
esis.  Int J Biochem Cell Biol 2006, 38(12):2018-2039.
13. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z: Development of
heparanase inhibitors for anti-cancer therapy.  Curr Med Chem
2006, 13(18):2101-2111.
14. Simizu S, Ishida K, Osada H: Heparanase as a molecular target
of cancer chemotherapy.  Cancer Sci 2004, 95(7):553-558.
15. Shafat I, Barak AB, Postovsky S, Elhasid R, Ilan N, Vlodavsky I, Arush
MW: Heparanase levels are elevated in the plasma of pediat-
ric cancer patients and correlate with response to anticancer
treatment.  Neoplasia 2007, 9(11):909-916.
16. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, Sin-
delka R, Sjoback R, Sjogreen B, Strombom L, Stahlberg A, Zoric N:
The real-time polymerase chain reaction.  Mol Aspects Med
2006, 27(2–3):95-125.
17. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA,
Kozlowski JM, McEwan RN: A rapid in vitro assay for quantitat-
ing the invasive potential of tumor cells.  Cancer Res 1987,
47(12):3239-3245.
18. Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, Platt JL,
S h e n  J ,  G a t t u s o  P ,  P r i n z  R A :  Inverse correlation between
heparan sulfate composition and heparanase-1 gene expres-
sion in thyroid papillary carcinomas: a potential role in
tumor metastasis.  Clin Cancer Res 2003, 9(16 Pt 1):5968-5979.
19. Onisto M, Slongo ML, Gregnanin L, Gastaldi T, Carli M, Rosolen A:
Expression and activity of vascular endothelial growth factor
and metalloproteinases in alveolar and embryonal rhab-
domyosarcoma cell lines.  Int J Oncol 2005, 27(3):791-798.
20. McKenzie EA: Heparanase: a target for drug discovery in can-
cer and inflammation.  Br J Pharmacol 2007, 151(1):1-14.
21. Hulett MD, Hornby JR, Ohms SJ, Zuegg J, Freeman C, Gready JE, Par-
ish CR: Identification of active-site residues of the pro-meta-
static endoglycosidase heparanase.  Biochemistry 2000,
39(51):15659-15667.
22. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schu-
bert S, Flugelman MY, Vlodavsky I, Ilan N: Processing and activa-
tion of latent heparanase occurs in lysosomes.  J Cell Sci 2004,
117(Pt 11):2249-2258.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:304 http://www.biomedcentral.com/1471-2407/9/304
Page 10 of 10
(page number not for citation purposes)
23. Nadav L, Eldor A, Yacoby-Zeevi O, Zamir E, Pecker I, Ilan N, Geiger
B, Vlodavsky I, Katz BZ: Activation, processing and trafficking of
extracellular heparanase by primary human fibroblasts.  J Cell
Sci 2002, 115(Pt 10):2179-2187.
24. Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I, Li
JP: Newly generated heparanase knock-out mice unravel co-
regulation of heparanase and matrix metalloproteinases.
PLoS ONE 2009, 4(4):e5181.
25. Quiros RM, Rao G, Plate J, Harris JE, Brunn GJ, Platt JL, Gattuso P,
Prinz RA, Xu X: Elevated serum heparanase-1 levels in
patients with pancreatic carcinoma are associated with poor
survival.  Cancer 2006, 106(3):532-540.
26. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-
Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I:
Mammalian heparanase: gene cloning, expression and func-
tion in tumor progression and metastasis.  Nat Med 1999,
5(7):793-802.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/304/pre
pub